Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Abeona Therapeutics, the most common co-covered peer. Each story carries 2 original sources on average, compared with 4.3 for the broader beat in this window.
Last mentioned: Mar 16, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Abeona Therapeutics, the most common co-covered peer. Each story carries 2 original sources on average, compared with 4.3 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 5.9 for that window. We currently track 1 Healthcare story that mention Krystal Biotech, all published on March 16, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Krystal Biotech. Shared-story counts are live from our verified record — not editorial picks.
Abeona Therapeutics is set to report its fiscal year 2025 results, marking its transition from a clinical-stage developer to a commercial-stage biopharmaceutical entity. The primary focus for investors is the commercial trajectory of ZEVASKYN® for recessive dystrophic epidermolysis bullosa (RDEB) and the company's ability to manage complex cell therapy logistics.
Source: Seeking Alpha · Seeking Alpha
Krystal Biotech is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
